On September 5th, the U.S. FDA granted full approval for our medicine to slow kidney function decline in adults with IgA nephropathy. For more information, see our Press Release.
Search for information about a product, therapeutic area or event
Media, investors, advocacy organizations and others, please contact us here.
For US healthcare professionals only
The purpose of this Travere Therapeutics Medical Affairs website is to support healthcare professionals with scientific information. This website is also a channel for US healthcare professionals to submit questions or connect with Travere Therapeutics US healthcare professionals. The information provided is for educational purposes only and is not intended to promote any products. By continuing to use this site you are acknowledging that you are a US healthcare professional
Sparsentan Improves Glomerular Endothelial and Podocyte Functions and Augments Protective Tissue Repair in a Mouse Model of Focal Segmental Glomerulosclerosis (FSGS)
The Dual Endothelin Type A Receptor (ETAR) and Angiotensin II Type 1 Receptor (AT1R) Antagonist, Sparsentan, Protects Against the Development of Albuminuria and Glomerulosclerosis in the gddY Mouse Model of IgA Nephropathy
The Dual Endothelin Type A Receptor (ETAR) and Angiotensin II Type 1 Receptor (AT1R) Antagonist, Sparsentan, Protects Against the Development of Albuminuria and Glomerulosclerosis in the gddY Mouse Model of IgA Nephropathy